Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2011 Apr;11(2):105-11. doi: 10.1016/j.coph.2010.11.001. Epub 2010 Dec 2.

Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE).

Author information

  • 1Department of Biomedical Sciences, Cedars-Sinai Medical Center, 110 N. George Burns Rd, Los Angeles, CA 90048, USA.


Angiotensin-converting enzyme (ACE) can cleave angiotensin I, bradykinin, neurotensin and many other peptide substrates in vitro. In part, this is due to the structure of ACE, a protein composed of two independent catalytic domains. Until very recently, little was known regarding the specific in vivo role of each ACE domain, and they were commonly regarded as equivalent. This is not true, as shown by mouse models with a genetic inactivation of either the ACE N- or C-domain. In vivo, most angiotensin II is produced by the ACE C-domain. Some peptides, such as the anti-fibrotic peptide AcSDKP, are substrates only of the ACE N-domain. Knowing the in vivo role of each ACE domain has great significance for developing ACE domain-specific inhibitors and for understanding the full effects of the anti-ACE pharmaceuticals in widespread clinical use.

Published by Elsevier Ltd.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk